SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
X	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* SINGAPORE BIO INNOVATIONS PTE LTD (Last) (First) (Middle) 250 NORTH BRIDGE ROAD #20-02 RAFFLES CITY TOWER (Street) SINGAPORE 179101 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol KALOBIOS PHARMACEUTICALS INC [ KBIO ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 02/05/2013
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/05/2013		C		472,013(4)	A	(1)	474,018	D(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B-1 Preferred Stock	(1)	02/05/2013		C			121,149(2)	(1)	(1)	Common Stock	121,149(1)(2)	$0	0	D(3)
Series B-2 Preferred Stock	(1)	02/05/2013		C			175,489(2)	(1)	(1)	Common Stock	175,489(1)(2)	$0	0	D(3)
Series C Preferred Stock	(1)	02/05/2013		C			51,710(2)	(1)	(1)	Common Stock	56,595.9(1)(2)	$0	0	D(3)
Series D Preferred Stock	(1)	02/05/2013		C			104,387(2)	(1)	(1)	Common Stock	118,779.1(1)(2)	$0	0	D(3)

1. Name and Address of Reporting Person* SINGAPORE BIO INNOVATIONS PTE LTD (Last) (First) (Middle) 250 NORTH BRIDGE ROAD #20-02 RAFFLES CITY TOWER (Street) SINGAPORE 179101 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

1. Name and Address of Reporting Person* EDB Investments Pte Ltd. (Last) (First) (Middle) 250 NORTH BRIDGE ROAD #20-03 RAFFLES CITY TOWER (Street) SINGAPORE 179101 (City) (State) (Zip) Relationship of Reporting Person(s) to Issuer Director X 10% Owner Officer (give title below) Other (specify below)

Explanation of Responses:

1. The Series B-1 Convertible Preferred Stock and Series B-2 Convertible Preferred Stock converted into the common stock of the Issuer on a 1-for-1 basis and had no expiration date. Series C Convertible Preferred Stock converted into the common stock of the Issuer on a 1-for-1.09 basis and had no expiration date. Series D Convertible Preferred Stock converted into the common stock of the Issuer on a 1-for-1.14 basis and had no expiration date.

2. Reflects a 1-for-3.56147 reverse stock split which became effective on January 15, 2013.

3. EDB Investments Pte Ltd ("EDBI"), as the parent entity of Singapore Bio-Innovations Pte Ltd, beneficially owns the reported securities indirectly. The Economic Development Board of Singapore ("EDB"), a Singapore government entity, is the parent entity of EDBI. EDBI, EDB and the Singapore government may be deemed to have shared voting and dispositive power over the securities owned beneficially and of record by Singapore Bio-Innovations Pte Ltd.

4. Represents the sum of all converted shares described in Table II of this Form 4. The converted shares were first aggregated on a per Reporting Person basis and then rounded down to the next whole share.

Remarks:

	/s/ Lowell Segal, on behalf of Singapore Bio-Innovations Pte Ltd. as its attorney-in-fact	02/07/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.